Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

被引：5

作者：

Chang, Lung-Ji ^{[1
,2
,3
]}

Li, Yuhua ^{[4
]}

Tu, Sanfang ^{[4
]}

Lai, Xun ^{[5
,6
]}

Huang, Rui ^{[4
]}

Tsao, Shih-Ting ^{[1
]}

Liu, Yu-Chen ^{[1
]}

Zhang, Rui ^{[1
]}

Deng, Lan ^{[4
]}

Zhou, Xuan ^{[4
]}

Zhang, Hongyu ^{[7
]}

Zhang, Wenli ^{[7
]}

Li, Yuchen ^{[1
]}

机构：

[1] Genoimmune Med Inst, Shenzhen, Peoples R China

[2] UESTC, Sch Med, Chengdu, Sichuan, Peoples R China

[3] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA

[4] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China

[5] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Dept Hematol, Kunming, Yunnan, Peoples R China

[6] Yunnan Boya Hosp, Dept Hematol, Kunming, Yunnan, Peoples R China

[7] Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-114396

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

225

引用

页数：3

共 50 条

[1] Phase I/II Trial of Multi Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 13 - 14
[2] Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas
Zhang, Rui
Li, Yuhua
Tu, Sanfang
Huang, Rui
Lai, Xun
Zhang, Leping
Zvonkov, Eugene E.
Savchenko, Valeriy G.
Gabeeva, Nelly G.
Liu, Yuchen
Li, Yuchen
Jiao, Cheng
Deng, Lan
Zhou, Xuan
Zhang, Hongyu
Zhang, Wenli
Chang, Lung-Ji
BLOOD, 2020, 136
[3] 4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas
Jiao, Cheng
Zvonkov, Eugene
Lai, Xun
Zhang, Rui
Liu, Yuchen
Qin, Yue
Savchenko, Valery
Gabeeva, Nelly
Chung, Tsai-Hua
Sheng, Liyuan
Chang, Lung-Ji
BLOOD CANCER JOURNAL, 2021, 11 (03)
[4] 4SCAR2.0: a multi-CAR-T therapy regimen for the treatment of relapsed/refractory B cell lymphomas
Cheng Jiao
Eugene Zvonkov
Xun Lai
Rui Zhang
Yuchen Liu
Yue Qin
Valery Savchenko
Nelly Gabeeva
Tsai-Hua Chung
Liyuan Sheng
Lung-Ji Chang
Blood Cancer Journal, 11
[5] A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
Chen, Xinfeng
Li, Xin
Liu, Yanfen
Zhang, Zhen
Zhang, Xudong
Huang, Jianmin
Li, Hong
Li, Feng
Zhang, Lei
Li, Ling
Wu, Xiaolong
Ma, Wang
Sun, Zhenchang
Yu, Hui
Zhou, Zhiyuan
Feng, Xiaoyan
Cui, Kang
Li, Zhaoming
Zhang, Hongling
Zeng, Ying
Wan, Xiaochun
Chen, Youhai H.
Zhang, Mingzhi
Zhang, Yi
IMMUNOTHERAPY, 2020, 12 (10) : 681 - 696
[6] Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
Schuster, Stephen J.
Svoboda, Jakub
Nasta, Sunita Dwivedy
Porter, David L.
Chong, Elise A.
Mahnke, Yolanda
Lacey, Simon F.
Melenhorst, J. Joseph
Chew, Anne
Shah, Gaurav
Hasskarl, Jens
Litchman, Manuel
Wasik, Mariusz A.
Landsburg, Daniel J.
Mato, Anthony R.
Garfall, Alfred L.
Frey, Noelle V.
Marcucci, Katherine T.
Shea, Joanne
McConville, Holly
Zheng, Zhaohui
Levine, Bruce L.
June, Carl H.
BLOOD, 2014, 124 (21)
[7] Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+lymphomas.
Schuster, Stephen J.
Svoboda, Jakub
Nasta, Sunita
Porter, David L.
Mato, Anthony
Shah, Gaurav D.
Landsburg, Daniel Jeffrey
Chong, Elise A.
Lacey, Simon F.
Melenhorst, Jan J.
Chew, Anne
Hasskarl, Jens
Shah, Nirav Niranjan
Wasik, Mariusz A.
Marcucci, Katherine
Zheng, Zhaohui
Levine, Bruce
June, Carl H.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China
Dong, Lujia
Chang, Lung-Ji
Gao, Zhiyong
Lu, Dao-Pei
Zhang, Jian-Ping
Wang, Jing-Bo
Zhang, Le-Ping
Chen, Yu-Hong
Zheng, Hu-Yong
Liu, Ting
Niu, Ting
Huang, He
Liu, Rong
Wang, Heng-Xiang
Gao, Li
Yang, Tong-Hua
Lai, Xun
BLOOD, 2015, 126 (23)
[9] Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Zhou, Xuan
Tu, Sanfang
Wang, Chunsheng
Huang, Rui
Deng, Lan
Song, Chaoyang
Yue, Chunyan
He, Yanjie
Yang, Jilong
Liang, Zhao
Wu, Anqin
Li, Meifang
Zhou, Weijun
Du, Jingwen
Guo, Zhenling
Li, Yongqian
Jiao, Cheng
Liu, Yuchen
Chang, Lung-Ji
Li, Yuhua
FRONTIERS IN IMMUNOLOGY, 2020, 11
[10] A Phase Ib/II Study of Anti-CD30 Chimeric Antigen Receptor T Cells for Relapsed/Refractory CD30+Lymphomas
Grover, Natalie S.
Park, Steven I.
Ivanova, Anastasia
Eldridge, Paul
McKay, Kathryn
Cheng, Catherine
Laing, Spencer
Covington, Deborah
West, John
Sharf, Elizabeth
Morrison, J. Kaitlin
Scott, Shaw
Crecelius, Erin
Shelley, Desirae
Alexander, Maurice
Buchanan, Faith Brianne
Kassam, Emily
McElfresh, Megan
Pinto, Alicia
Spruill, Angela
Zanter, Ashley
Wehner, Kimberly
Dittus, Christopher
Shea, Thomas C.
Dotti, Gianpietro
Serody, Jonathan S.
Beaven, Anne
Savoldo, Barbara
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)

← 1 2 3 4 5 →